|
3rd
Annual
BIOTECHNOLOGY INDUSTRY CONFERENCE
May 15, 2003 ~ The Harvard Club, NYC
27 West 44th Street, between
Fifth and Sixth Avenues
AGENDA
REGISTER
FOR THIS EVENT
Download
the PDF Brochure
8:00 AM
Conference Registration & Breakfast
9:00 AM
Industry Roundtable: The
Big Picture: What's the Buzz on Biotech?
▪ Restructuring, Consolidation & Changing FDA
Approval Process
▪ Has the industry gotten past the ImClone fiasco?
▪ How does Big Pharma fit in the biotech landscape?
▪ Where does the industry think the short, mid and long-term
opportunities?
Panelists:
Alan E. Smith Ph.D., CSO &
SVP Research, Genzyme
Peter Feinstein, General Partner,
Bioventures Investors
Michael Lytton, Partner, Oxford Bioscience Partners
Andrew Meadow, General Partner, HealthCon Corp
Owen Garrick, MD, Executive
Director & Global Head of M&A Negotiations,
Novartis Pharmaceuticals
Moderator:
Jim Shrine, Managing Editor,
BioWorld
9:45 AM
Special Presentation:
Intellectual Property
Kevin Noonan, Partner,
McDonnell Boehnen Hulbert & Berghoff
10:15 AM
Networking Break
10:30 AM
Keynote Address
Dr. Lester Crawford, Deputy
Commissioner, FDA
11:00 AM
Mini-Roundtable: Has Biotech turned into
long-term investments?
▪ Homeland Security Budget Bonanza--Can Biotech thrive
on this opportunity?
▪ Developing new vaccines: Biotech's Hole-in-One?
▪ Can Bioinformatics and Genomics make a comeback?
Panelists:
Dr. Kenneth Carter Ph.D., President
& CEO, Avalon Pharmaceuticals
Gail Maderis, President, Genzyme Molecular Oncology
Dr. Jennie Mather Ph.D., President, Founder & CEO, Raven
Biotechnologies
Mark Leuchtenberger, President & CEO, Therion Biologics
Moderator:
Kevin DeGeeter, Editor, Fierce
Biotech
11:30 AM
Successful BioFinancing: Where's
the money and how is Biotech getting its hands on it?
▪ What's driving consolidation: cash or technology?
▪ What options exist in this tumultuous equity-financing
environment?
▪ Virtual suspension of the IPO market: Can Biotech
companies wait out the storm?
▪ Can jaded VCs still be of assistance? - greater
control, PIPEs, etc.
▪ Who are the top players in the financing marketplace?
Panelists:
Russell Wilson, CFO, Iomai Corporation
E. Kurt Kim, President & CEO,
Private Raise
Dr. Chris Mirabelli Ph.D., General Partner, HealthCare
Ventures LLC
Thomas Konatich, CFO/Acting CEO, SIGA Technologies
Dr. Srinivas Akkaraju Ph.D., Principal, JP Morgan Partners
Moderator:
Dr. Ginger Johnson Ph.D., Defined Health
12:30 PM
Luncheon
1:45 PM
Keynote Address: "Information
Based Medicine"
Dr. Joseph Jasinski, Worldwide
Operations Manager, IBM Life Sciences
2:15 PM
Special Presentation
Sweetening the Deal:
Giving Equity to Big Pharma as Part of a Strategic
Development Transaction
A
strategic development alliance with a major player in the
pharmaceutical industry is the time-honored way to get your
product to market.
An equity investment by the pharma in the biotech may
sweeten the deal, but it also may create difficulties for the
parties not found in a standard private placement of stock.
Does your pharmaceutical partner represent your most
obvious source of new capital, regardless of the potential
pitfalls?
Eileen Smith Ewing, Esq., Partner & Chair Life Sciences
Group, Kirkpatrick & Lockhart
LLP
2:45 PM
Wall Street Assesses the Industry
Leading Wall Street professionals examine the industry,
key players and direction in an in-depth interview. Valuable
opportunity to hear
directly from top analysts on the marketplace and preferred
stock selections, and ask your questions about specific
companies, technologies and forecasts. Audience
questions will be taken.
Additional speakers to be announced
Panelists:
Bill Tanner, Ph.D., Managing Director,
Head of Biotechnology, Leerink Swann
Frank DiLorenzo, Biotechnology Equity Analyst, Standard &
Poor's
Maged Shenouda, Analyst, JP Morgan
Moderator:
Terry McEvoy, Coordinating Editor,
The Wall Street Transcript
3:15 PM
Mini-Roundtable: NBIC--Convergence of
Biotech & Other Areas of Scientific Research
Nanotechnology, Software and new
approaches to science
▪ What are the opportunities and pitfalls?
▪ Who are the key players today and tomorrow?
▪ Is there potential for significant government funding
in this area?
Panelists:
Josh Wolfe, Co-Founder & Managing Partner, Lux Capital
Vijaya Vasista, COO, Nanosphere
Dr. Vladimir Makarov, Co-Founder & CSO, Rubicon Genomics
Dr. Juan Sanchez, Research Associate, Punk Ziegel
Moderator:
Salvatore Salamone, Senior IT Editor, Bio IT World
4:15 PM
NETWORKING RECEPTION
*Agenda subject
to change
Download
the PDF Brochure
REGISTER
FOR THIS EVENT For
information on sponsorships and presentations, please contact
Jay Livnat at (212) 952-7438 or jay@twst.com.
|
